Selank

What it is

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is structurally based on tuftsin (a tetrapeptide fragment of immunoglobulin G) with a tripeptide extension intended to increase metabolic stability. Selank is approved as a pharmaceutical in Russia (Селанк) for generalized anxiety disorder and asthenic conditions but has not received approval in the United States or Western Europe. Selank is not FDA-approved for any use in the United States.

The peptide was developed beginning in the 1980s as part of Russian research into peptide-based pharmaceuticals for neuropsychiatric indications. Selank and its sister peptide Semax belong to a class described as “regulatory peptides” — short, stable peptides studied for their interactions with native CNS systems.

Mechanism of action

Proposed mechanisms come from laboratory and animal research:

• GABAergic modulation: in animal studies, Selank has been reported to influence GABAergic neurotransmission.
• Serotonergic effects: changes in serotonin metabolism have been reported in animal models.
• BDNF and neurotrophic effects: increased brain-derived neurotrophic factor expression in the hippocampus has been reported in rats.
• Immune system effects: changes in certain cytokine and immunoglobulin levels have been reported, consistent with its tuftsin-derived origin.

Research findings

Studies conducted mainly in Russia have reported effects of Selank; these findings have not been evaluated by the FDA:

Generalized anxiety disorder: Russian clinical studies, including comparisons with medazepam (a benzodiazepine), have been published; benefit in people has not been established by the FDA. The Russian approval rests on this evidence base.

Asthenic conditions: the Russian indication covers conditions described as nervous exhaustion, post-illness fatigue, and adjustment disorders.

Cognitive measures: animal studies have reported changes in attention and learning measures; small studies in people have been published, but benefit in people has not been established.

The published literature is mostly in Russian-language journals, and independent replication in Western randomized trials is lacking. Well-controlled human trials establishing the effectiveness and safety of Selank are lacking.

Side effects and contraindications

Human safety has not been established in well-controlled trials outside Russia, and long-term effects are unknown. Products sold outside regulated channels (for example, as “research peptides”) may vary in purity, dose, and sterility.

Avoided in: pregnancy and breastfeeding, where safety data are lacking. Selank is not a substitute for evaluation and care of anxiety or other psychiatric conditions.

What we don’t yet know

Independent Western randomized trials have not replicated the Russian findings. Long-term safety with chronic or repeated use is not well characterized. How Selank compares with established anxiety treatments has not been documented in head-to-head studies meeting Western regulatory standards.